"Topline, phase 2 trial results with the antipsychotic drug pimavanserin (Nuplazid, Acadia Pharmaceuticals) in patients with Alzheimer's disease (AD) psychosis showed a statistically significant reduction in psychosis among those taking p"...
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rate observed in clinical practice.
The overall safety profile of Neuraceq is based on data from 1090 administrations of Neuraceq to 872 subjects. No serious adverse reactions related to Neuraceq administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain. All adverse reactions were mild to moderate in severity and of short duration. The most commonly reported adverse reactions (occurring in at least 1% of subjects) during Neuraceq clinical trials are shown in Table 2.
Table 2 : Adverse Reactions with a Frequency ≥ 1%
Reported in Clinical Trials (n = 1090 Administrations in 872 Subjects)
|Adverse drug reaction||n (%)|
|Injection / application site erythema||18 (1.7)|
|Injection site irritation||12 (1.1)|
|Injection site pain||37 (3.4)|
Read the Neuraceq (florbetaben f 18 injection) Side Effects Center for a complete guide to possible side effects
Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/9/2016
Additional Neuraceq Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.